Glaucoma Trial, Recruiting NCT06993597 Sponsor: University of Maryland, Baltimore Condition: Glaucoma
Back to Glaucoma

Glaucoma Trial, Recruiting

NCT06993597
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 years or older
  • People who have been diagnosed with primary open-angle glaucoma (a common type of glaucoma where fluid drainage in the eye is reduced), or people with no history of glaucoma (who would participate as a comparison group)
  • People whose eye examination shows an open drainage angle in the eye (a specific measurement called Shaffer grade 3 or 4)
  • People whose vision, when corrected with glasses or contact lenses, is 20/25 or better
  • People whose prescription falls within a moderate range — between +3.00 and -5.00 diopters (not too far-sighted or too short-sighted)
  • People who have never previously used eye drop medications for glaucoma
  • People diagnosed with high-pressure glaucoma (eye pressure of 22 mmHg or higher recorded on 3 visits), normal-pressure glaucoma (eye pressure of 21 mmHg or lower recorded on 3 visits), or people with a healthy optic nerve and normal visual fields who are a similar age to those with glaucoma (comparison group)

Who may not be able to join:

  • People with corneal (front surface of the eye) problems that could interfere with certain pressure-measurement tests used in the trial
  • People with retinal diseases that affect the nerve fibre layer of the eye (for example, conditions causing pulling or traction on the central part of the retina)
  • People who have had any previous eye surgery or laser treatment to the eye
  • People who have been diagnosed with diabetes
  • People with a history of uveitis (inflammation inside the eye)
  • People who have used steroid medications (such as cortisone or prednisone) for a long period of time
  • People with neurological or other whole-body conditions such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, or schizophrenia
  • People whose visual field test results are considered unreliable
  • People who have medical reasons why they cannot take a type of medication called beta blockers — for example, a very slow heart rate or severe lung disease
  • People with moderate to severe glaucoma, based on a specific grading system used by eye specialists (Hodapp-Anderson-Parrish criteria)
  • People who have a history of wearing contact lenses
  • People with low blood pressure

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Osamah Saeedi, MD, University of Maryland, Baltimore

Phone: 16672141232

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 September 2025
Est. completion
1 March 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Corneal Biomechanical Modulus

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov